Aristotle University Of Thessaloniki (AUTH)
Κλινική και φαρμακοκινητική μελέτη της τιγεκυκλίνης σε ασθενείς με λοιμώδη έξαρση χρόνιας αποφρακτικής πνευμονοπάθειας
Abstract
dc:descriptionTigecycline is a glycylcycline belonging to the newest Group 3 of the tetracyclines, characterized by a broad spectrum of antimicrobial activity against Gram positive, Gram negative and anaerobic bacteria, as well as against some non-tuberculous mycobacteria. Tigecycline has been in clinical use for the past 15 years and is approved for complicated intra-abdominal, skin and skin structure infections in both Europe and U.S.A., as well as for community acquired bacterial pneumonia in U.S.A. Soon after its official release in 2005, several meta-analyses occurred warning about decreased effectiveness and excess mortality in critically ill patients with respiratory infections receiving tigecycline. Such data along with an FDA box warning in 2013, led to the frequent empirical use of tigecycline in higher dosage regimens while new pharmacokinetic studies are conducted, in search of the reasons leading to its poor effectiveness. The purpose of our study was to assess the clinical and pharmacokinetic profile of tigecycline in patients with an infectious Chronic Obstructive Pulmonary Disease exacerbation. Despite tetracyclines in general are indicated for use in infectious COPD exacerbations, by both GOLD recommendations and our national guidelines, tigecycline has a limited spectrum of indications by both FDA and EMA and is not used for infectious COPD exacerbations in clinical practice. 11 patients hospitalized due to an infectious COPD exacerbation received the recommended tigecycline regimen (100mg loading dose followed by 50mg twice a day), on top of standard care with anti-inflammatory medication and inhaled bronchodilators. Blood and sputum samples were collected from each patient after administration of the seventh tigecycline dose, in steady state, on the time points: 0 (12 hours after the previous tigecycline dose), 1 hour (on completion of tigecycline i.v. infusion), 2,3,4,6,9 and 12 hours (before administration of the ensuing tigecycline dose). 81 plasma and 73 sputum samples were collected and analyzed by an LC-MS/MS method developed for the purposes of our study. Estimated tigecycline plasma and sputum concentrations were plotted against time and the corresponding pharmacokinetic data were analyzed using a noncompartmental model by WinNonlin v.8.3 software. Tigecycline’s clinical effectiveness was evaluated by means of resolution of abnormal clinical findings on admission and improved laboratory and pulmonary function findings on hospital exit. Symptoms recurrence, need for readmission and pulmonary function were evaluated 6 months after hospital exit. Mean tigecycline clearance was found 15.97±21.33L/h and half-life time (T1/2) was found 17.18±10.91h. Mean values of volume distribution was found 151.94±75.43L. In plasma, the mean maximum tigecycline concentration was 975.95±490.36ng/mL and mean minimum concentration 214.48±140.62ng/mL. Mean plasma AUC0-12 value was 3765.90±1862.22ng*h/mL. In sputum, the mean maximum concentration was 641.90±253.07ng/mL and mean minimum concentration was 308.05±61.77ng/mL. Mean sputum AUC0-12 value was 4023.27±793.36ng*h/mL. The lung penetration ratio for tigecycline, estimated by the sputum AUC0-12/plasma AUC0-12, was 1.65±1.35. We also conducted penetration ratio estimation by using the free plasma AUC0-12 and we found a much-elevated value of 8.25±6.78. In the pharmacodynamic part of our study, the pharmacodynamic index of interest for tigecycline is freeAUC0-24/MIC and was calculated by dividing plasma freeAUC0-24 with the only available FDA MIC breakpoint for Streptococcus pneumoniae (MIC0.06mcg/mL) and Haemophilus influenzae (MIC0.25 mcg/mL). Mean freeAUC0-24/MIC ratio for S. pneumoniae was 25.10±12.42 and for H. influenzae was 6.02±2.97. Our 11 patients study group was found to have two distinct characteristics compared to the patients studied in previous tigecycline pharmacokinetic studies. Firstly, degree of infection was different in our study, as patients suffered from mild to severe exacerbation of their chronic pulmonary disease, opposed to acute bacterial pneumonia and severe systematic illness in the existing pharmacokinetic studies. The second distinct characteristic is the high mean body mass index value of our study group, in the range of obesity. Pharmacokinetic results in our study are in line with the limited and heterogenous existing data. Tigecycline plasma concentrations and AUC0-12 values are in line with the limited data from studies where the same tigecycline regimen was administered. Values of sputum tigecycline concentrations and AUC0-12 are in accordance with the limited existing data. In The modest estimation of volume of distribution is most likely attributed to the elevated body mass index value of our study group in combination with the hydrophilic tigecycline profile. Penetration ratio values estimated by either way used are in line with the limited existing data and highlights tigecycline satisfactory lung penetration. Regarding non severely ill patients, a tigecycline AUC/MIC value 12.8, was reported to be predictive of clinical efficacy in community acquired pneumonia. In our study, none of the patients achieved this efficacy threshold for H. influenzae and 3 out of 11 patients did not achieve it for S. pneumoniae. On the other hand, in a Monte Carlo stimulation evaluating the standard tigecycline regimen, tigecycline was found to be highly effective against Gram-positive strains but not against Gram-negative bacteria, while in our study, PD results also support a better effect against S. pneumoniae compared to the Gram-negative H. influenzae. Our study adds to the limited available intrapulmonary pharmacokinetic data in a real-life ward setting of hospitalized COPD patients. The obtained results are subject to the limited number of patients studied and the sputum samples used to evaluate the tigecycline lung penetration. The tigecycline pharmacokinetic profile at a standard dosage regimen supports its clinical effectiveness against commonly causative bacteria of COPD exacerbations and highlights its sufficient lung penetration in pulmonary infections of moderate severity.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kipourou, Maria
- Κηπουρού, Μαρία
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/55419